Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...
Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...
Cipla and Lilly partner to distribute Yurpeak (tirzepatide) in India for type 2 diabetes and weight management. Broader ...
Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...
Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...
In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...
Austin Schrock on MSN
Three Principles That Unlock Your Peak Potential
This collection of videos centers on rapid personal transformation through small, intentional shifts in mindset and daily ...
Lilly and Cipla announce a distribution agreement for Yurpeak, a drug for type 2 diabetes and weight management, enhancing ...
Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...
Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...
Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...
Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback